A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

NCT06361875 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

910

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza Immunization

Interventions

BIOLOGICAL: Quadrivalent Influenza mRNA Vaccine MRT5421
BIOLOGICAL: Quadrivalent Influenza mRNA Vaccine MRT5424
BIOLOGICAL: Quadrivalent Influenza mRNA Vaccine MRT5429
BIOLOGICAL: Quadrivalent Influenza Standard Dose Vaccine
BIOLOGICAL: Quadrivalent Influenza High-Dose Vaccine
BIOLOGICAL: Quadrivalent Recombinant Influenza Vaccine

Sponsor

Sanofi Pasteur, a Sanofi Company